Clinical trials: Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus
Study of the Safety of Substituting Exenatide for Insulin in Patients Using Insulin and Oral Antidiabetic Agents
This study will look at the safety of substituting exenatide for insulin in patients with type 2 diabetes who are currently taking insulin and oral antidiabetic agent(s).
- Trial name
- NCT00099333
- Testing
- exenatide, Insulin
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants With Type 2 Diabetes Mellitus
The purpose of this study is to examine the participant's preference for treatment with once-weekly dosing of DPP-4 inhibitor trelagliptin versus once-daily dosing of DPP-4 inhibitor alogliptin among the participants with type 2…
- Trial name
- TRINITY (NCT03231709)
- Testing
- Trelagliptin, Alogliptin
- Where
- 2 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the efficacy and safety of 2 different doses of canagliflozin compared with placebo in older patients (55 to 80 years of age) with type 2 diabetes mellitus (T2DM) with inadequate control…
- Trial name
- NCT01106651
- Testing
- Canagliflozin 100 mg, Canagliflozin 300 mg, Antihyperglycemic agent(s)
- Where
- 86 sites in United States, Australia and 15 more
- Volunteers
- 716 people
- Sponsor
- Janssen Research & Development, LLC
Type 2 Diabetes Mellitus, Hypercholesterolemia
A Multicenter Study to Evaluate the Cholesterol Lowering Effects of Two Marketed Products in Patients With Type 2 Diabetes Mellitus and Hypercholesterolemia (MK-0653A-077)
The purpose of this 10-week study is to compare the reduction in cholesterol following treatment with two different marketed drugs, in patients with type 2 diabetes mellitus and hypercholesterolemia.
- Trial name
- NCT00110435
- Testing
- MK0653A, ezetimibe (+) simvastatin, Comparator: atorvastatin
- Volunteers
- 1,229 people
- Sponsor
- Organon and Co
Type 2 Diabetes
A Study on Switching From Daily DPP-4 Inhibitor to HSK7653 in Type 2 Diabetes Patients
To assess the effectiveness of HSK7653 tablets following the substitution of daily DPP-4 inhibitor (DPP-4i) over a 24-week treatment period.
- Trial name
- NCT06703268
- Testing
- HSK7653 10 mg, Daily DPP-4 inhibitor
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Type 2 Diabetes (T2DM)
Evaluate the Efficacy and Safety of GZR33 Injection in Patients With Type 2 Diabetes
Evaluate the efficacy of GZR33 Injection and Insulin Degludec Injection (Tresiba®) in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Oral Antidiabetic Drugs.
- Trial name
- NCT07527078
- Testing
- GZR33 Injection, Insulin Degludec Injection (Tresiba®)
- Where
- China
- Volunteers
- 350 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Diabetes Mellitus Type 1
A Study of the Safety and Efficacy of Pancreatic Endocrine Cell Clusters Implanted Into the Omentum of Type 1 Diabetes Patients With Severe Hypoglycemia
This study will evaluate the safety, efficacy and durability of SR-02 administered to the omentum of patients of Type 1 diabetes with severe recurrent hypoglycemia. The study will also help establish the optimal treatment dose.
- Trial name
- SUGR (NCT06651515)
- Testing
- Allogeneic Pancreatic Endocrine Cell Clusters
- Where
- 2 sites in United States
- Sponsor
- Seraxis
Diabetes
A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of saxagliptin administered before breakfast for 14 consecutive days in patients with type 2 diabetes mellitus.
- Trial name
- NCT01162876
- Testing
- saxaglipitin
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Diabetes Mellitus, Type 2
A Study of LY2922470 in Healthy Participants and Participants With Diabetes
The aim of this trial is to evaluate the safety of the study drug in healthy participant and participant with diabetes. It will investigate how much of the study drug gets into the blood stream and how long it takes the body to…
- Trial name
- NCT01746017
- Testing
- LY2922470
- Where
- Singapore
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
The primary purpose of this research study is to determine the cardiovascular and renal effectiveness and safety of empagliflozin compared to dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with Type 2 Diabetes Mellitus…
- Trial name
- NCT05465317
- Testing
- Empagliflozin, Dipeptidyl Peptidate-4 inhibitors
- Where
- United States
- Volunteers
- 62,197 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus Type 2
A Dose-Finding Study of RO4998452 in Patients With Diabetes Mellitus
This 6 arm study will evaluate the efficacy, safety and pharmacokinetics of 5 doses of RO4998452 compared to placebo in patients with type 2 diabetes mellitus.
- Trial name
- NCT00800176
- Testing
- RO4998452
- Where
- 67 sites in United States, Australia and 10 more
- Volunteers
- 394 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
Insulin Glulisine in Type 2 Diabetic Patients
To evaluate the efficacy of a single injection of glulisine before the main meal added to insulin glargine plus oral antidiabetic drugs (OADs) compared to insulin glargine plus OADs in Type 2 diabetic patients poorly controlled…
- Trial name
- Basal Plus (NCT00360698)
- Testing
- Insulin Glargine, Glimepiride, Insulin Glulisine
- Where
- 3 sites in United States, Russia and 1 more
- Volunteers
- 106 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes
The objective of the study is to investigate the efficacy, safety and tolerability of linagliptin 5 mg qd compared to placebo given for 24 weeks in inadequately controlled T2DM patients on empagliflozin 10 mg or 25 mg and maximum…
- Trial name
- NCT01778049
- Testing
- BI 10773, BI 10773 / BI 1356
- Where
- 114 sites in United States, Argentina and 9 more
- Volunteers
- 708 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin)
Primary objective: To find out an optimal regimen of OHA (oral hypoglycaemic agents) in combination with insulin glargine (metformin, glimepiride or metformin+glimepiride) by measuring HbA1c level Secondary objective: To compare…
- Trial name
- NCT00708578
- Testing
- Glimepiride, Metformin, Insulin Glargine
- Where
- South Korea
- Volunteers
- 99 people
- Sponsor
- Sanofi
Dyslipidemia, Glucose Metabolism Disorder
Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI
Under conditions of first-line drug treatment in antidiabetic drug naïve/drug free patients with type 2 diabetes mellitus and dyslipidemia, to show that :- the efficacy of a fixed combination (FC) of fenofibrate and metformin on…
- Trial name
- NCT00361868
- Testing
- fenofibrate (F) + metformin (M) hydrochloride fixed combination, Rosiglitazone
- Where
- 70 sites in Croatia, Finland and 6 more
- Volunteers
- 88 people
- Sponsor
- Solvay Pharmaceuticals
Endothelial Dysfunction, Diabetes Mellitus
Endothelial Disfunction Treatment With Glimepiride/Metformin Combination (Glimetal) in Type 2 Diabetes Patients
The Purpose of this study was to evaluate the effect of the combination glimepiride/metformin over endothelial dysfunction (ED) in asymptomatic patients with type 2 diabetes mellitus (DM) using 13N-ammonia-positron emission…
- Trial name
- NCT01429818
- Testing
- Glimepiride/metformin, Metformin
- Where
- Mexico
- Volunteers
- 16 people
- Sponsor
- Laboratorios Silanes S.A. de C.V.
T2DM (Type 2 Diabetes Mellitus)
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes
The goal of this clinical study is to evaluate the efficacy and safety of Berberine Ursodeoxycholate (HTD1801) compared to placebo in patients with type 2 diabetes, inadequately controlled with diet and exercise alone.
- Trial name
- SYMPHONY-1 (NCT06350890)
- Testing
- HTD1801
- Where
- 56 sites in China
- Volunteers
- 408 people
- Sponsor
- Shenzhen HighTide Biopharmaceutical Ltd.
Type 2 Diabetes Mellitus
A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus
GX-G6-002 is a Phase 2, 12-week, randomized, parallel group, multi-centre, double blind, placebo-controlled and an open-label active comparator study.
- Trial name
- NCT03962010
- Testing
- GX-G6, Control
- Volunteers
- 78 people
- Sponsor
- Genexine, Inc.
Type 2 Diabetes
MK-0431/ONO-5435 Phase III Clinical Trial-Rapid-acting Insulin Secretagogue Add-on Study in Patients With Type 2 Diabetes
This Phase III clinical trial will examine the safety, tolerability, and efficacy of the addition of MK-0431/ONO-5435 to Japanese patients with Type 2 Diabetes mellitus who have inadequate glycemic control on diet/exercise…
- Trial name
- NCT01517321
- Testing
- MK-0431/ONO-5435
- Where
- 6 sites in Japan
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
Empagliflozin (BI 10773) Dose Finder Study in Japanese Patients With Type 2 Diabetes Mellitus
This study is conducted to determine the most appropriate therapeutic doses of BI 10773 in Japanese patients with T2DM at first treatment period.
- Trial name
- NCT01193218
- Testing
- BI 10773
- Where
- 32 sites in Japan
- Volunteers
- 547 people
- Sponsor
- Boehringer Ingelheim
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.